JZJiarui Zhang

Jiarui Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jiarui Zhang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Anbang Hu

    Department of General Surgery, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Street, Nangang District, Harbin, China

    1 shared publication
  • Baoliang Guo

    Department of General Surgery The Second Affiliated Hospital of Harbin Medical University Harbin China

    1 shared publication
  • Bo Lyu

    College of Food Science and Engineering, Jilin Agricultural University, Changchun 130118, China; Division of Soybean Processing, Soybean Research & Development Center, Chinese Agricultural Research System, Changchun 130118, China

    1 shared publication
  • Fanjing Kong

    Department of General Surgery, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Street, Nangang District, Harbin, China

    1 shared publication
  • Fei Ma

    Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

    1 shared publication
  • Hansong Yu

    College of Food Science and Engineering, Jilin Agricultural University, Changchun 130118, China

    1 shared publication

Latest Publications

  • Open Access

    Clinical Radiologic Analysis of 2964 Papillary Breast Lesions

    by Hanyu Zhang, Anbang Hu, Yanling Li, Mingcui Li, Zhiyuan Rong, Weilun Cheng, Yansong Liu, Yunqiang Duan, Jianyuan Feng, Ziang Chen, et al.

    Background: Clinical management of papillary breast lesions (PBLs) remains controversial. Our objective was to analyze the independent risk factors associated with malignant PBLs.Methods: A retrospective review of clinical variables in 2964 patients with papillary lesions available for evaluation.Results: This retrospective study screened that older patients (≥ 50 years), postmenopausal, palpable tumor, tumor size ≥ 15 mm, peripheral tumor, and tumor with calcification were independent risk factors affecting malignant PBLs. Moreover, the probability of malignant PBLs without the appealed risk factors was only 3.4%.Conclusions: Patients without risk factors for papillary lesions can manage their health with imaging surveillance. The choice of surgical treatment for the remaining patients is a reasonable recommendation.


  • Insoluble Dietary Fiber from Okara Combined with Intermittent Fasting Treatment Synergistically Confers Antiobesity Effects by Regulating Gut Microbiota and Its Metabolites

    by Sainan Wang, Junyao Wang, Jiarui Zhang, Wenhao Liu, Wendan Jing, Bo Lyu, Hansong Yu, Zhao Zhang

    Insoluble dietary fiber (IDF) was recently revealed to have an antiobesity impact. However, the impact and potential mechanism of high-purity IDF derived from okara (HPSIDF) on obesity caused by a high-fat diet (HFD) remain unclear. Except for dietary supplementation, intermittent fasting (IF) has attracted extensive interest as a new dietary strategy against obesity. Thus, we hypothesize that HPSIDF combined with IF treatment may be more effective in preventing obesity. In this study, HPSIDF combined with IF treatment synergistically alleviated HFD-induced dyslipidemia, impaired glucose homeostasis, systemic inflammation, and fat accumulation. Furthermore, gut microbiota dysbiosis and lowered short-chain fatty acid synthesis were recovered by HPSIDF combined with IF treatment. Meanwhile, metabolomic analysis of feces revealed that HPSIDF combined with IF treatment obviously reversed the alterations of metabolic pathways and differential metabolites induced by HFD, which were linked to the modulations of the gut microbiota. Collectively, our findings indicated that HPSIDF combined with IF treatment has great potential to substantially enhance antiobesity efficacy by modulating the gut microbiota and its metabolites.